natgillin/translations-raw huggingface dataset:
The primary efficacy endpoint was change from baseline in clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at the end of the treatment period.
Primarni opazovani dogodek učinkovitosti je bila sprememba najnižjega FEV1 glede na izhodišče na kliničnem obisku (pred bronhodilatatorjem in pred odmerkom) do konca obdobja zdravljenja.
The primary efficacy endpoint was CIN2+ associated with HPV-16 and/or HPV-18 (HPV-16/18).
Primarni opazovani dogodek učinkovitosti je bil CIN2+, povezan s HPV-16 in/ali HPV-18 (HPV- 16/18).
The primary efficacy endpoint was defined as a decrease in total Positive and Negative Syndrome Scale (PANSS) scores as shown in the following table.
Primarni cilj za dokaz učinkovitosti je bil določen kot zmanjšanje skupne ocene po lestvici pozitivnih in negativnih simptomov (Positive and Negative Syndrome Scale-PANSS), kot je prikazano v spodnji preglednici.
The primary efficacy endpoint was ORR, and OS was also evaluated.
Primarni opazovani dogodek glede učinkovitosti je bil ORR, vrednotili pa so tudi OS.
The primary efficacy endpoint was ORR, based on Response Evaluation Criteria in Solid Tumours (RECIST).
Primarna končna točka učinkovitosti je bila objektivni odziv na zdravljenje (ORR), ocenjen po merilih RECIST (Response Evaluation Criteria in Solid Tumours).
The primary efficacy endpoint was overall survival (OS).
Primarni cilj študije je bil doseženo celokupno preživetje (OS – overall survival).
The primary efficacy endpoint was progression free survival (PFS) by International Myeloma Working Group (IMWG criteria).
Primarni cilj študije je bilo preživetje brez napredovanja (PFS, progression free survival) po kriterijih Mednarodne delovne skupine za plazmocitom (IMWG, International Myeloma Working Group).
The primary efficacy endpoint was progression free survival (PFS).
Primarna končna točka učinkovitosti je bila preživetje brez napredovanja bolezni (PFS – progression free survival).
The primary efficacy endpoint was proportion of subjects achieving ≥35% reduction from baseline in spleen volume at week 24 as measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT).
Primarni cilj opazovanja za oceno učinkovitosti je bil delež preiskovancev, pri katerih je po 24 tednih prišlo do zmanjšanja volumna vranice za ≥35 % od izhodiščne vrednosti, kar so izmerili s pomočjo magnetno- resonančnega (MR) slikanja ali računalniške tomografije (CT).
The primary efficacy endpoint was the change from baseline at week 16 in 6-minute walk distance (6MWD).
Glavni opazovani dogodek učinkovitosti je bila sprememba razdalje, prehojene na 6-minutnim testom hoje, od začetka študije do 16. tedna.
The primary efficacy endpoint was the incidence of proven/probable IFIs at 16 weeks post-randomization as determined by an independent, blinded external expert panel.
Primarni opazovani dogodek učinkovitosti je bila pojavnost dokazanih oziroma verjetnih invazivnih glivnih okužb 16 tednov po randomizaciji, ki jih je ugotavljala neodvisna skupina zunanjih strokovnjakov na slep način.
The primary efficacy endpoint was the intraocular pressure (IOP) change from baseline at Week 12 of the study.
Primarni cilj študije učinkovitosti je bila sprememba očesnega tlaka (IOP) glede na začetne vrednosti v 12. tednu študije.
The primary efficacy endpoint was the mean change from baseline of the Unified Parkinson’s Disease Rating Scale (UPDRS) Part II (activities of daily living) score plus Part III motor score at week 30 or early termination.
Primarni opazovani dogodek učinkovitosti je bila povprečna sprememba rezultata 2. dela enotne ocenjevalne lestvice za Parkinsonovo bolezen (UPDRS- Unified Parkinson’s Disease Rating Scale) (vsakodnevne dejavnosti) in 3. dela (ocena motorične funkcije) glede na izhodišče po 30 tednih ali do predčasne prekinitve zdravljenja.
The primary efficacy endpoint was the mean difference in the coefficient of fat absorption (CFA-72h) between Enzepi and placebo treatment.
Primarni opazovani dogodek učinkovitosti je bila povprečna razlika v koeficientu absorpcije maščob (CFA– 72h) med zdravilom Enzepi in placebom.
The primary efficacy endpoint was the patient global assessment of method of pain control at 24 hours used to test equivalence between IONSYS and intravenous PCA morphine using a pre-specified ± 10% equivalence boundary with a 2-sided 95% confidence interval.
Primarni opazovani dogodek učinkovitosti je bila bolnikova celovita presoja metode obvladovanja bolečine po 24 urah, ki so jo uporabili za ugotavljanje enakovrednosti med zdravilom IONSYS in intravenskim zdravljenjem PCA z morfinom z vnaprej določeno ±10- odstotno mejo enakovrednosti in dvostranskim 95-odstotnim intervalom zaupanja.
The primary efficacy endpoint was the proportion (%) of subjects that reached normalisation of bowel movements defined as an average of three or more spontaneous, complete bowel movements (SCBM) per week over the 12-week treatment period.
Primarni opazovani dogodek učinkovitosti je bil delež (%) oseb, ki so dosegle normalizacijo odvajanja blata, opredeljen kot povprečje treh ali več spontanih popolnih odvajanj blata (SCBM – spontaneous, complete bowel movements) na teden v 12- tedenskem obdobju zdravljenja.
The primary efficacy endpoint was the time to onset of symptom relief using a visual analogue scale (VAS).
V študijah faze III je bil primarni pokazatelj učinkovitosti čas do nastopa olajšanja simptomov, določen z uporabo vizualne analogne lestvice (VAS – visual analogue scale).
The primary efficacy endpoint was TTP while the secondary efficacy endpoints were OS and ORR (CR+PR), using the European Group for Blood and Marrow Transplantation (EBMT) criteria.
Po kriterijih Evropske skupine za transplantacijo kostnega mozga (EBMT – European Group for Blood and Marrow Transplantation) je bil primarni opazovani dogodek glede učinkovitosti TTP, sekundarna opazovana dogodka pa OS in ORR (CR+PR).
The primary efficacy endpoints were:
Primarna opazovana dogodka učinkovitosti sta bila:
The primary efficacy outcome (all stroke, transient ischemic attack, non-CNS systemic embolism, MI and cardiovascular death) occurred in 5 (0.5 %) patients in the rivaroxaban group (n = 978) and 5 (1.0 %) patients in the VKA group (n = 492; RR 0.50; 95 % CI 0.15-1.73; modified ITT population).
Primarni izid za oceno učinkovitosti (vse možganske kapi, prehodni ishemični napadi, sistemske embolije izven osrednjega živčevja, miokardni infarkt ali kardivaskularna smrt) se je zgodil pri 5 (0,5 %) bolnikih, v skupini, ki je prejemala rivaroksaban (n = 978) in 5 (1.0 %) bolnikih, v skupini, ki je prejemala antagoniste vitamina K (n = 492; razmerje tveganja 0,50; 95 % interval zaupanja 0,15 – 1,73; modificirana ITT populacija).
The primary efficacy outcome measure of these two trials was objective response rate (ORR) according to RECIST v1.1 as evaluated by a Blinded Independent Central Review (BICR).
Primarno merilo izida učinkovitosti v teh dveh preizkušanjih je bil objektivni delež odziva (ORR – objective response rate) po merilih RECIST v1.1, kot je bil ocenjen s slepljenim neodvisnim centralnim pregledom (BICR – Blinded Independent Central Review).
The primary efficacy outcome measure was ORR as assessed by independent review using RECIST 1.1. Secondary efficacy outcome measures were disease control rate (DCR; including complete response, partial response and stable disease), response duration, PFS and OS.
Primarno merilo izida učinkovitosti je bil ORR, ocenjen po neodvisni presoji na podlagi RECIST 1.1. Sekundarna merila izida učinkovitosti so bila delež nadzora nad boleznijo (DCR, vključno s popolnim odgovorom, delnim odgovorom in stabilno boleznijo), trajanje odgovora, preživetje brez napredovanja bolezni in celokupno preživetje.
The primary efficacy outcome measure, based on investigator assessed tumour response, was progression-free survival (PFS) of the lenvatinib plus everolimus arm vs the everolimus arm and of the lenvatinib arm vs the everolimus arm.
Glavno merilo izida učinkovitosti na podlagi odziva tumorja, ki ga je ocenil raziskovalec, je bilo preživetje brez napredovanja bolezni (progression-free survival - PFS) skupine z lenvatinibom in everolimusom proti skupini z everolimusom in skupine z lenvatinibom proti skupini z everolimusom.
The primary efficacy outcome measures were OS and PFS as assessed by blinded independent central review (BICR) using RECIST 1.1. Secondary efficacy outcome measures were ORR and response duration.
Primarni merili izida učinkovitosti sta bili celokupno preživetje in preživetje brez napredovanja bolezni, ocenjeno s slepim neodvisnim centralnim pregledom (BICR – blinded independent central review) na podlagi meril RECIST 1.1. Sekundarni merili izida učinkovitosti sta bila ORR in trajanje odgovora.
The primary efficacy outcome measures were PFS as assessed by IRO using RECIST version 1.1 and OS.
Primarni merili izida učinkovitosti sta bili preživetje brez napredovanja bolezni, ocenjeno po IRO na podlagi meril RECIST, različica 1.1, ter celokupno preživetje.
The primary efficacy outcome measures were progression free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria in Solid Tumours [RECIST], version 1.1) and overall survival (OS).
Primarni merili izida učinkovitosti sta bili preživetje brez napredovanja bolezni (PFS, ocenjeno po integrirani radiološki in onkološki presoji [IRO] na podlagi meril RECIST, različica 1.1) ter celokupno preživetje (OS).
The primary efficacy parameter was the change from baseline to endpoint in ‘ON Time without troublesome dyskinesia’.
Parameter primarne učinkovitosti je bila sprememba od izhodišča do končne točke v trajanju obdobja brez težav z gibanjem (»vklop«), brez moteče diskinezije.
The primary efficacy variable was percent change in lumbar spine BMD, fracture efficacy was not evaluated.
Primarna spremenljivka učinkovitosti je bil odstotek spremembe mineralne kostne gostote v ledvenem delu hrbtenice; učinkovitost glede zlomov ni bila ocenjena.
The primary efficacy variable was the patient’s assessment of pain intensity.
Variabla primarne učinkovitosti je bila ocena intenzivnosti bolnikove bolečine.
The primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia (i.e. clearance of blasts from the marrow and the blood, but without a full peripheral blood recovery as for complete responses), or return to chronic phase CML.
Primarna učinkovitostna spremenljivka je bila stopnja hematološkega odziva, opisanega bodisi kot popolni hematološki odziv, kot odsotnost dokazov levkemije (tj. izginotje blastov iz kostnega mozga in krvi, a brez popolnega okrevanja periferne krvi kot pri popolnem odzivu) ali kot vrnitev v kronično fazo KML.
The primary endpoint and other week 48 outcomes (including outcomes by key baseline covariates) for SPRING-2 and SINGLE are shown in Table 3.
Primarni cilj in ostali rezultati po 48 tednih (vključno z rezultati po ključnih osnovnih spremenljivkah) študij SPRING-2 in SINGLE so prikazani v Preglednici 3.
The primary endpoint at Day 8 showed that dolutegravir 50 mg twice daily was superior to placebo, with an adjusted mean treatment difference for the change from Baseline in Plasma HIV-1 RNA of -1.2 log10 copies/mL (95% CI -1.5 - - 0.8log10 copies/mL, p<0.001).
Končni cilj na 8. dan je pokazal, da je bilo zdravljenje s 50 mg dolutegravirja dvakrat na dan boljše od placeba; prilagojena srednja razlika od izhodišča v plazemski HIV-1 RNA je bila -1,2 log10 kopij/ml (95% CI -1,5 -0,8 log10 kopij/ml, p<0,001).
The primary endpoint event rate was 11.9 % in patients who received a reduced dose (1microgram/kg/min) vs 11.2 % in patients who received the standard dose (2 microgram/kg/min) when eptifibatide was administered in the early routine fashion (p=0.81).
Delež primarnih opazovanih dogodkov je bil 11,9 % pri prejemnikih nižjega odmerka (1 mikrogram/kg/min) in 11,2 % pri prejemnikih standardnega odmerka (2 mikrograma/kg/min), če je bil eptifibatid uporabljen v zgodnjem rutinskem načinu (p = 0,81).
The primary endpoint for the study was progression-free survival (PFS) evaluated by RECIST (Response Evaluation Criteria in Solid Tumors), based on the investigator’s assessment (local radiology).
Primarni cilj opazovanja v študiji je bilo preživetje brez napredovanja bolezni, ki ga je raziskovalec (lokalni radiolog) ocenil s pomočjo Kriterijev za ocenjevanje odziva pri solidnih tumorjih (RECIST, Response Evaluation Criteria in Solid Tumours).
The primary endpoint for the two split-thickness skin graft trials was the intra- individual difference in time to wound closure (at least 95% epithelialisation) based on blinded photo evaluations.
Primaren cilj pri obeh študijah na ranah na mestu odvzema presadka delne debeline kože je bila intraindividualna razlika pri času do zaprtja rane (vsaj 95-odstotna epitelizacija) na podlagi slepih ocen fotografij.
The primary endpoint in RA studies VI and VII was injection site pain immediately after injection as measured by a 0-10 cm VAS.
Primarna končna točka v študijah revmatoidnega artritisa VI in VII je bila bolečina na mestu injiciranja takoj po injiciranju, izmerjena z vizualno analogno lestvico od 0 do 10 cm (VAS - Visual Analog Scale).
The primary endpoint in these studies was the proportion of patients who achieved PASI 75 response from baseline at week 12 (see Tables 4 and 5).
Primarni končni rezultat v teh študijah je bil delež bolnikov, ki so od začetka študije do 12. tedna dosegli odziv PASI 75 (glejte preglednici 4 in 5).
The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p = 0.0042 (median PFS: 11.4 vs.
Primarna končna točka v tej študiji, preživetje brez napredovanja bolezni (PFS), je bilo pomembno daljše v kraku TPF kot v kraku PF,
The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p=0.0042 (median PFS: 11.4 vs.
V kraku s TCF se je tveganje za napredovanje zmanjšalo za 32,1 %, ČDN pa je bil ob tem značilno daljši (p = 0,0004).
The primary endpoint of the study included progression free survival (PFS) in all patients.
Primarni cilj preskušanja je vključeval preživetje brez napredovanja bolezni (PFS) pri vseh.
The primary endpoint of the study was a reduction of serum calcium of
Primarni cilj študije je bilo znižanje kalcija v serumu za
The primary endpoint of the study was clinical remission at Week 26, defined as PCDAI score  10.
Primarni cilj študije je bila klinična remisija v 26.tednu, definirana kot vrednost PCDAI ≤ 10.
The primary endpoint of the study was corticosteroid-free clinical remission at week 26, defined as patients in clinical remission (CDAI of <150) who, for at least 3 weeks, had not taken oral systemic corticosteroids (prednisone or equivalent) or budesonide at a dose >6 mg/day.
Primarni končni opazovani dogodek študije je bila klinična remisija bolezni brez jemanja kortikosteroidov v 26. tednu, ki je bila opredeljena z bolniki v klinični remisiji (vrednost CDAI < 150), ki najmanj 3 tedne niso jemali peroralnih sistemskih kortikosteroidov (prednizona oziroma njemu enakovrednih kortikosteroidov) ali budezonida v odmerku > 6 mg/dan.
The primary endpoint of the study was met: a statistically significantly higher percentage of subjects in the Resolor group (37.9%) had an average of ≥ 3 SCBMs/week compared with subjects in the placebo treatment group (17.7%) (p<0.0001) over the 12-week double-blind treatment period.
Primarni cilj študije je bil izpolnjen: v 12-tedenskem dvojno slepem obdobju zdravljenja je imel statistično značilno večji odstotek preizkušancev v skupini Resolor (37,9 %) povprečno ≥ 3 SCBM/teden v primerjavi s preizkušanci v skupini, ki je prejemala placebo (17,7 %) (p < 0,0001).
The primary endpoint of the study was overall intracranial response rate (OIRR) in the V600E patient population, as assessed by investigators.
Primarni opazovani dogodek študije je bil celotni delež intrakranialnega odziva (OIRR – overall intracranial response rate) v populaciji bolnikov z V600E po raziskovalčevi oceni.
The primary endpoint of the study was overall survival with a key secondary endpoint of PFS.
Primarni cilj opazovanja v študiji je bila stopnja celokupnega preživetja, ključni sekundarni cilj opazovanja pa je bilo preživetje brez napredovanja bolezni (PFS).
The primary endpoint of the study was PFS by investigator assessment.
Primarni cilj preskušanja je bilo preživetje brez napredovanja bolezni (PFS), ocenjeno s strani raziskovalca.
The primary endpoint of the study was placebo-adjusted change from baseline in 6MWD at the last visit (week 12).
Primarni opazovani cilj študije je bila glede na placebo prilagojena sprememba prehojene razdalje v v testu šestminutne hoje od izhodiščne vrednosti do vrednosti pri zadnjem obisku (12. teden).
The primary endpoint of the study was the placebo adjusted change from baseline in 6-minute walk distance (6MWD) at the last visit (week 16).
Primarni opazovani cilj študije je bila glede na placebo prilagojena sprememba prehojene razdalje v testu šestminutne hoje (6MWD – 6-minute walk distance) od izhodiščne vrednosti do vrednosti pri zadnjem obisku (16. teden).
The primary endpoint of the study was to evaluate the efficacy of trametinib compared to chemotherapy with respect to progression-free survival (PFS) in patients with advanced/metastatic BRAF V600E mutation-positive melanoma without a prior history of brain metastases (N = 273) which is considered the primary efficacy population.
Primarni opazovani dogodek študije je bila ocena učinkovitosti trametiniba v primerjavi s kemoterapijo, kar zadeva preživetje brez napredovanja (PFS – progression-free survival) pri bolnikih z napredovalim/metastatskim melanomom s pozitivno mutacijo BRAF V600E in brez anamneze metastaz v možganih (n = 273), ki veljajo za primarno populacijo učinkovitosti.
The primary endpoint of the trial was the skeletal morbidity period rate (SMPR).
Primarni cilj raziskave je bil stopnja hitrosti obolevnosti okostja (SMPR – skeletal morbidity period rate).
The primary endpoint of the trials was the skeletal morbidity period rate (SMPR).
Primarni cilj raziskave je bil stopnja hitrosti obolevnosti okostja (SMPR – skeletal morbidity period rate).
The primary endpoint of the two studies was the carbon monoxide (CO) confirmed, 4 week continuous quit rate (4W-CQR) from week 9 through week 12.
Glavni opazovani dogodek v obeh študijah je bil z ogljikovim monoksidom (CO) preverjeni odstotek 4-tedenske trajne opustitve kajenja (4W-CQR – “4-week continuous quit rate”) od 9. do 12. tedna.
The primary endpoint of the two studies was the carbon monoxide (CO) confirmed, 4-week continuous quit rate (4W-CQR) from week 9 through week 12.
Glavni opazovani dogodek v obeh študijah je bil z ogljikovim monoksidom (CO) preverjeni odstotek 4-tedenske trajne opustitve kajenja (4W-CQR – “4-week continuous quit rate”) od 9. do 12. tedna.
The primary endpoint of therapeutic response was a composite serological endpoint requiring suppression of HBV DNA to < 5 log10 copies/ml in conjunction with either loss of serum HBeAg or ALT normalised.
Primarni cilj opazovanja za ocenjevanje odziva na zdravljenje je bil sestavljen serološki izvid, ki je vključeval supresijo HBV DNA na <5 log10 kopij/ml skupaj z bodisi izgubo HBeAg v serumu ali normalizacijo ALT.
The primary endpoint of this study was the response rate to vaccination, defined as the percentage of patients with a serum bactericidal antibody (SBA) titre ≥ 8 at the week 5 visit.
Primarni opazovani dogodek te študije je bila stopnja odziva na cepljenje, ki je opredeljena kot odstotek bolnikov s titrom serumskih baktericidnih protiteles (SBA) ≥ 8 ob študijskem kontrolnem pregledu v 5. tednu.
The primary endpoint of this trial was progression free survival (PFS), based on trial investigators’ assessment of disease progression.
Primarni cilj tega preskušanja je bilo preživetje brez napredovanja bolezni (PFS), osnovano na oceni napredovanja bolezni s strani raziskovalcev.
The primary endpoint showed non- inferiority (predefined margin of 12%) of ACR 20 response after 12 months of treatment, 64.8% (206/318) for the abatacept SC group and 63.4% (208/328) for the adalimumab SC group; treatment difference was 1.8% [95% confidence interval (CI): -5.6, 9.2], with comparable responses throughout the 24-month period.
Primarni opazovani dogodek je pokazal neinferiornost (vnaprej določena meja 12 %) odziva ACR 20 po 12 mesecih zdravljenja, ki je bil v skupini z abataceptom s.c. dosežen pri 64,8 % (206/318) bolnikov, v skupini z adalimumabom s.c. pa pri 63,4 % (208/328); razlika zdravljenja je bila 1,8 % [95 % interval zaupanja (IZ): -5,6; 9,2], odzivi v celotnem 24-mesečnem obdobju pa so bili primerljivi.
The primary endpoint showed non- inferiority (predefined margin of 12%) of ACR20 response after 12 months of treatment, 64.8% (206/318) for the abatacept SC group and 63.4% (208/328) for the adalimumab SC group; treatment difference was 1.8% [95% confidence interval (CI): -5.6, 9.2], with comparable responses throughout the 24-month period.
Primarni opazovani dogodek je pokazal neinferiornost (vnaprej določena meja 12 %) odziva ACR 20 po 12 mesecih zdravljenja, ki je bil v skupini z abataceptom s.c. dosežen pri 64,8 % (206/318) bolnikov, v skupini z adalimumabom s.c. pa pri 63,4 % (208/328); razlika zdravljenja je bila 1,8 % [95 % interval zaupanja (IZ): -5,6; 9,2], odzivi v celotnem 24-mesečnem obdobju pa so bili primerljivi.
The primary endpoint was best confirmed response to retreatment as assessed by EBMT criteria.
Primarna ocena učinkovitosti je bil najboljši potrjeni odziv na ponovno zdravljenje, skladno z EBMT- kriteriji.
The primary endpoint was complete patient clearance 12 weeks after the last photodynamic therapy.
Primarna končna točka je bila popolna odstranitev lezij pri bolnikih 12 tednov po zadnjem fotodinamičnem zdravljenju.
The primary endpoint was complete patient clearance after 12 weeks following the last photodynamic therapy.
Primarna končna točka je bila popolna odstranitev lezij bolnikov 12 tednov po zadnjem fotodinamičnem zdravljenju.
The primary endpoint was complete remission (CR) rate that was assessed by independent expert review.
Primarni cilj opazovanja je bil delež bolnikov s popolno remisijo po oceni neodvisnega strokovnjaka.
The primary endpoint was complete response in the delayed phase (25 to 120 hours following initiation of chemotherapy) in Cycle 1.
Primarni opazovani dogodek je bil popoln odziv v zapozneli fazi (od 25 do 120 ur po uvedbi kemoterapije) v 1. ciklusu.
The primary endpoint was durable response rate (DRR) [defined as the percent of patients with complete response (CR) or partial response (PR) maintained continuously for a minimum of 6 months] per blinded central review.
Primarni opazovani dogodek je bil delež trajnega odziva (DRR – durable response rate) [opredeljen kot odstotek bolnikov s popolnim odzivom (CR – complete response) ali delnim odzivom (PR – partial response), ki se je neprekinjeno ohranil vsaj 6 mesecev] po oceni slepljenega centralnega pregleda.
The primary endpoint was investigator assessed PFS.
Primarni cilj študije je bilo preživetje brez napredovanja bolezni (PFS, progression free survival).
The primary endpoint was objective response rate (ORR) as assessed by an independent review facility (IRF) as summarised in Table 2.
Primarni cilj preskušanja je bil delež objektivnega odziva (ORR – objective response rate), kakor ga je ocenila neodvisna ustanova za pregled (IRF – independent review facility), kot je povzeto v preglednici 2.
The primary endpoint was OS and secondary endpoints included PFS.
Primarni opazovani dogodek je bilo celokupno preživetje, sekundarni opazovani dogodki pa so vključevali preživetje brez napredovanja bolezni.
The primary endpoint was OS.
Primarni opazovani dogodek je bilo celokupno preživetje.
The primary endpoint was OS.
Primarni opazovani dogodek je bilo OS.